A controlled study of consumption of beta-glucan-enriched soups for 2 months by type 2 diabetic free-living subjects.
Type 2 diabetes is associated with a higher cardiovascular risk and there has been a growing interest in using dietary intervention to improve lipid profile and glucose control. The present work aims at analysing the effects of the enrichment of a normal diet with beta-glucan (3.5 g/d) in free-living type 2 diabetic subjects for 2 months, using a palatable soup. This trial was a parallel, placebo-controlled, double-blinded randomised study performed in fifty-three type 2 diabetic subjects. During a 3-week run-in period, subjects daily consumed a ready meal control soup (without beta-glucan). For the following 8 weeks, subjects were randomly assigned to consume daily either a control soup or a beta-glucan soup. Changes in lipid profile (total cholesterol (TC), HDL- and LDL-cholesterol (HDLc and LDLc), apo B and TAG) and in glucose control (HbA1c and fasting glucose) were measured. There was no significant alteration in lipid profile in the two groups (TC, HDLc, LDLc and apo B). TAG decreased significantly in the beta-glucan group compared with the control group ( - 0.12 (SD 0.38) v. 0.12 (SD 0.44) mmol/l, P = 0.03). HbA1c and fasting glucose were not reduced in any group. A single daily ingestion of 3.5 g beta-glucan, as required by official dietary recommendations, for 8 weeks did not change the lipid profile and HbA1c in type 2 diabetic subjects. To improve the metabolic profile of type 2 diabetic subjects in the long term, the quantity, the food vectors and the tolerability of beta-glucan products may be re-evaluated.
Centre de Recherche en Nutrition Humaine de Rhône-Alpes, F-69495 Pierre-Bénite, France.
Christine
C
Cugnet-Anceau
Julie-Anne
JA
Nazare
Maria
M
Biorklund
Elodie
E
Le Coquil
Agnès
A
Sassolas
Monique
M
Sothier
Jorgen
J
Holm
Mona
M
Landin-Olsson
Gunilla
G
Onning
Martine
M
Laville
Philippe
P
Moulin
D000368:Aged; D018554:Avena; D001786:Blood Glucose / Q000187:drug effects / Q000378:metabolism; D001835:Body Weight; D002097:C-Reactive Protein / Q000187:drug effects / Q000378:metabolism; D002318:Cardiovascular Diseases / Q000453:epidemiology* / Q000517:prevention & control; D008076:Cholesterol, HDL / Q000097:blood / Q000187:drug effects; D008078:Cholesterol, LDL / Q000097:blood / Q000187:drug effects; D003924:Diabetes Mellitus, Type 2 / Q000097:blood / Q000150:complications / Q000503:physiopathology*; D003925:Diabetic Angiopathies / Q000453:epidemiology* / Q000517:prevention & control; D003927:Diet, Diabetic; D004311:Double-Blind Method; D006442:Glycated Hemoglobin / Q000187:drug effects / Q000378:metabolism; D006801:Humans; D008055:Lipids / Q000097:blood*; D008875:Middle Aged; D010919:Placebos; D012307:Risk Factors; D011795:Surveys and Questionnaires; D047071:beta-Glucans / Q000494:pharmacology* / Q000627:therapeutic use
D001786:Blood Glucose; D002097:C-Reactive Protein; D008076:Cholesterol, HDL; D008078:Cholesterol, LDL; D006442:Glycated Hemoglobin; D008055:Lipids; D010919:Placebos; D047071:beta-Glucans